Stability Testing for FDA Approved KSHNO14 ( Pyridostigmine Bromide Extend – Release Tablets )

2026-11-03

This Sources Sought notice is issued for market research purposes only to identify potential sources capable of supporting FDA compliant stability testing for FDA approved KSHN014 ( Pyridostigmine Bromide Extend – Release Tablets ) 105 mg tablet for five ( 5 ) years at CRT and ten ( 10 ) years refrigerated , manufactured by Amneal Complex Research LLC and packaged in Blister Pack throughout the in - use period . The government is specifically seeking information on vendors capable of assuming or supporting long term stability testing including continued continuity requirements associated with an existing ongoing stability study . This notice is not a solicitation for proposals , and no award will be made as a result of this notice . CPE CBRN Medical CDP has an ongoing stability study in support of FDA approved KSHN014 ( Pyridostigmine Bromide Extend – Release Tablets ) 105 mg tablets , the study includes multiyear stability testing including long term and refrigerated storage conditions with stability data . The government is conducting market research to determine whether there are additional responsible sources capable of meeting the full scope of technical regulatory and continuity requirements associated with this effort .

Maryland

2026-05-02